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The insulin sensitizers, thiazolidinediones (TZDs), have been used as anti-diabetic drugs since the discovery of their
ability to alter insulin resistance through transactivation of peroxisome proliferator-activated receptors (PPARs).
However, their side effects in hepatitis, cardiovascular diseases, and bladder cancer resulted in some selling
restrictions in the USA and Europe. Here, we found that the potential impact of TZDs on the prostate cancer (PCa)
progression might be linked to the TR4 nuclear receptor expression. Clinical surveys found that 9% of PCa patients
had one allele TR4 deletion in their tumors. TZD increased cell growth and invasion in PCa cells when TR4 was
knocked down. In contrast, TZD decreased PCa progression in PCa cells with wild type TR4. Mechanism
dissection found that the Harvey Rat Sarcoma (HRAS) oncogene increased on TZD treatment of the TR4 knocked-
down CWR22Rv1 and C4-2 cells, and interruption with HRAS inhibitor resulted in reversal of TZD-induced PCa
progression. Together, these results suggest that TZD treatment may promote PCa progression depending on the
TR4 expression status that may be clinically relevant since extra caution may be needed for those diabetic PCa
patients receiving TZD treatment who have one allele TR4 deletion.
Neoplasia (2015) 17, 339–347Introduction
Thiazolidinediones (TZDs), including rosiglitazone, pioglitazone,
ciglitazone, and troglitazone, have been used extensively as successful
anti-diabetic drugs after the discovery of their ability to alter the insulin
sensitivity through activation of peroxisome proliferator-activated
receptor gamma (PPARG, NR1C3) [1,2]. However, side effectsincluding hepatotoxicity, cardiovascular diseases, and bladder cancer
have restricted some of their sales/usage in the USA and Europe [3–6].
Early studies indicated that TZDs might have protective effects in lung
cancer but not in colorectal, prostate, or breast cancers [7,8]. Other
reports suggested that TZDs could also reduce prostate cancer (PCa) cell
growth [9]. However, an early report suggested that continued TZDof Excellence (MOHW104-TDU-B-212-113002). Disclosure statement: The authors have
nothing to disclose.
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Figure 1. Nine percent of PCa patients have TR4 deletion. Sixty-nine
PCa specimens were tested by FISH. Six of 69 cancer samples
showed one TR4 allele deletion, while none of the normal
compartments of those 69 samples showed TR4 deletion. The
statistical results were calculated using Fisher exact test (*P b 0.05).
340 TZDs differential effects on prostate cancer Lin et al. Neoplasia Vol. 17, No. 4, 2015treatment in diabetic patients might lead to increased bladder cancer risk
in some patients [10], which raised a concern whether continued TZD
treatment in diabetic patients might also have risks of promoting
progression of other cancers.
Recent unexpected findings [11] showing TZDs could also function as
ligands/activators to activate the TR4 nuclear receptor (TR4, NR2C2)
[12–19] raised an interesting question about the potential impacts of this
newly identifiedTZD-TR4 signaling on the classic TZD-PPAR signaling.
Here, we found 9% of PCa patients had lost one allele ofTR4 gene in
their tumors compared to their adjacent benign tissues. In vitro cell lines
and in vivomice studies also found that the TR4 expression status in PCa
might be able to alter the TZD's ability to induce PCa progression, which
might raise a concern for those selective diabetic PCa patients receiving
TZD treatment who had one allele TR4 deletion.
Materials and Methods
Prostate Tissue Microarray
A tissuemicroarray (TMA), consisting of representative lesions (three
cores each) of benign appearing prostate and prostatic carcinoma from
the tissue specimens obtained by radical prostatectomy, was construc-
ted, as described previously [20]. Appropriate approval from the
Institutional Review Board was obtained before construction and use of
the TMA.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed by the
University of Rochester Medical Center Pathology Laboratory. Green
5-fluorescein dUTP-labeled human BAC clone RPCI-11 1104I16
probes for human TR4 were purchased from Empire Genomics
(Buffalo, NY) and we followed their protocol for hybridization.
Cell Culture
The PCa cell lines CWR22Rv1 and C4-2 were maintained in RPMI
1640 (Gibco, Grand Island, NY) supplemented with 10% FBS and 1%
antibiotic-antimycotic (Invitrogen,Grand Island,NY). StableCWR22Rv1
and C4-2 cell lines expressing scramble siRNA (scr) or siRNA against TR4
(siTR4) were established by transfecting pSuperior.retro.puro plasmids
into the cells and selecting for stable cell lines by treatment with
puromycin (1.2 μg/ml) for 2 weeks.
RNA Extraction and Quantitative Real-Time Polymerase
Chain Reaction Analysis
Total RNA was isolated using TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions and 3 μg of total RNA was subjected
to reverse transcription using Superscript III transcriptase (Invitrogen).
Quantitative real-time reverse transcription–polymerase chain reaction
(PCR) was conducted using a Bio-Rad CFX96 System with SYBR
Green to determine the level of mRNA expression of a gene of
interest. Expression levels were normalized to the expression of
β-actin RNA.
Cell Proliferation Assay
Cells were treated with 4 μM TZD (all treatments used
rosiglitazone) or DMSO vehicle control for 2 weeks before the
assay. C4-2 and CWR22Rv1 cells were seeded in 24-well plates
(10,000 cells per well) and cultured for 24, 48, 72, and 96 hours.
Cells were harvested and cell numbers were calculated using
3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide
(MTT) agent.Anchorage-Independent Colony Forming Assay
Cells were treated with 4 μM TZD or vehicle as control (DMSO)
for 1 month before the assay. C4-2 and CWR22Rv1 cells were
suspended at a density of 2 × 105 cells/ml in 0.4%Noble agar (Sigma,
St Louis, MO) containing media and were seeded on top of 0.8%
agarose containing media in culture plates, and after agarose
solidified, we added 2 ml of media on top. Media were changed
every week for 1 month. Colonies were stained with p-iodonitrote-
trazolium violet (Sigma), photographed, and counted.
Boyden Chamber Transwell Migration and Invasion Assays
Cells were treated with 4 μMTZD or DMSO for 2 months before
the migration assay. Migration assay was performed using 24-well
transwell inserts (8 μm pores) according to the manufacturer’s
instructions (Corning, #3422). C4-2 and CWR22Rv1 cells at 105
cells per well were seeded on the upper chambers of transwell plates
andmedia containing 20% FBS (10%more than the upper chamber)
were added to the lower chambers. For the invasion assay, the upper
chambers with 8 μM pore polycarbonate membrane insert were
pre-coated with Matrigel. Each sample was assayed in triplicate and
incubated for 24 hours. The cells that migrated into the lower
chambers were stained using 1% toluidine blue and counted under
a microscope.
Luciferase Reporter Assay
Harvey Rat Sarcoma (HRAS) promoter (−2053 to +144) was cloned
to pGL3 luciferase plasmid. Cells were co-transfected with pGL3-HRAS
promoter with pRL-TK as an internal control. Cells were lysed and
detected for firefly luciferase activity by adding substrate LAR II. The
internal Renilla luciferase control was detected by adding Stop & Glo
Reagent (Promega, Madison, WIS).
HRAS-Specific Inhibitor Treatment
HRAS-specific inhibitor farnesyl thiosalicylic acid (FTS) was
purchased from Cayman Chemical (Ann Arbor, MI). Cells were
treated with 50 μMFTS for 2 weeks. Themigration and invasion assays
were performed after treatment.
Orthotopic Xenograft Model
All animal procedures were approved by the Animal Care
and Use Committee of the University of Rochester. Male 6-
to 8-week-old nude mice were purchased from the National
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Figure 2. TZD treatment increases CWR22Rv1-siTR4 cell growth and colony formation. (A) Quantitative PCR showed TR4 mRNA level in
CWR22Rv1-siTR4 and CWR22Rv1-scr cell lines. (B) TZD treatment increases CWR22Rv1-siTR4 (left panel) cell growth compared to no
effect on CWR22Rv1-scr (right panel) using MTT assay. (C and D) TZD treatment increases CWR22Rv1-siTR4 (C) compared to decreases
CWR22Rv1-scr (D) cell colony formation in soft agar gel. The numbers of colonies were counted, and the quantifications were shown in
the right panels. All statistical analyses were performed using Student's t test (**P b 0.01).
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mixture was orthotopically injected into both anterior prostates
in nude mice at 8 weeks of age. The primary and metastatic
tumors were evaluated at 4 weeks endpoint.Western Blot Analysis
CWR22Rv1 cells were lysed in RIPA buffer [50 mM Tris-HCl
(pH 7.4), 1% NP‐40, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF,
1 mM Na3VO4, 1 mM NaF, 1 mM okadaic acid and 1 mg/ml
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Figure 3. TZD treatment increases CWR22Rv1-siTR4 cell migration and invasion. (A and B) TZD treatment increases CWR22Rv1-siTR4 (A)
but decreases CWR22Rv1-scr (B) cell migration compared to vehicle control using Boyden chamber transwell migration assay. (C and D)
TZD treatment increases CWR22Rv1-siTR4 (C) but has no effect on CWR22Rv1-scr (D) cell invasion compared to vehicle control using
Boyden chamber transwell invasion assay coated with Matrigel. The numbers of colonies were counted, and the quantifications were
shown in the right panels. All statistical analyses were performed using Student's t test (*P b 0.05, ***P b 0.001, ns = not significant).
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Figure 4. TZD treatment increases CWR22Rv1-siTR4 tumor formation
andmetastasis in vivo. CWR22Rv1 (1×106)withMatrigelmixturewas
orthotopically injected into both anterior prostates in five nudemice at
8 weeks of age. The primary andmetastatic tumors were evaluated at
4 weeks endpoint. (A) TZD treatment increases CWR22Rv1-siTR4
(siTR4_TZD) xenograft tumor (N = 10) size when injected into nude
mice prostate compared to CWR22Rv1-scr (scr_TZD) control (N= 8).
The pictures (upper panel) represent the prostate tumor grown in the
nude mice. The statistic results were calculated using Student's t test
and shown in the lower panel (***P b 0.001). (B) TZD treatment
increases CWR22Rv1-siTR4 xenograft tumor metastasis when
injected into nudemice prostate compared to CWR22Rv1-scr control.
The incidence of metastasis was calculated as shown in the lower
panel. The upper panel shows the large liver metastasis (arrow) in the
CWR22Rv1-siTR4 TZD-treated mouse. The statistical results were
calculated using Fisher exact test (*P b 0.05).
Neoplasia Vol. 17, No. 4, 2015 TZDs differential effects on prostate cancer Lin et al. 343aprotinin, leupeptin, and pepstatin]. Individual samples (50 μg of
proteins) were prepared for electrophoresis on 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and then transferred onto
poly(vinylidene) fluoride (PVDF) membranes (Millipore, Billerica,
MA). After blocking the membranes with 5% fat-free milk in TBST
[50 mM Tris (pH 7.5), containing 0.15 M NaCl and 0.05% Tween‐
20] for 1 hour at room temperature, the membranes were incubated
with appropriate dilutions (diluted in 2.5% BSA) of specific Raf-1
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at
4°C. After Tris buffered saline with Tween 20 (TBST) washing, the
blots were incubated with anti‐rabbit secondary antibodies with HRP
and conjugated for 1 hour. After TBSTwashing, the blots were developed
in ECL mixture (Thermo Fisher Scientific Inc., Rochester, NY).
Statistics
The data values were presented as the mean ± SEM. P values were
calculated by unpaired Student's t test or Fisher exact test. P b 0.05
was considered statistically significant.
Results
Nine Percent of PCa Patients Have One Allele TR4 Deletion
We tested TR4 deletion in a prostate TMA by FISH and found 9%
(6 of 69) of PCa specimens had one allele TR4 deletion. In contrast,
none of the control tissues/benign compartments from these 69
patients showed TR4 deletion (P b 0.0279; Figure 1). There were no
statistically significant differences in TR4 deletion among different
tumor grades [1/25 Gleason score (GS) ≤6 vs 5/38 GS 7 vs 0/6 GS
≥8 tumors had the deletion] or stages (4/53 pT2 vs 2/16 pT3 tumors
had the deletion). Additionally, no significant correlation between
TR4 deletion and tumor recurrence was seen. These findings in
clinical samples suggested a potential linkage between TR4 deletion
and the development and progression of PCa.
TZD Treatment–Altered PCa Cell Growth Is Linked to the
TR4 Expression Status
To test if TR4 deletion in PCa may be linked to PCa progression,
we examined the effects of TZD treatment on PCa cells with altered
TR4 expression to mimic the one allele TR4 deletion, since a recent
report suggested that TZD treatment might be linked to the increased
risk of bladder cancer [6], and importantly, TZD was also able to
function as an agonist to transactivate TR4 [11]. We were interested
to see if TZD treatment had any potential differential effects on the
PCa progression in those PCa cells with or without TR4 deletion.
We first applied TR4-siRNA to knock down TR4 in PCa
CWR22Rv1 cells (CWR22Rv1-siTR4) that led to nearly 50%
suppression of TR4 mRNA (Figure 2A) and then treated the cells with
TZD versus DMSO control. Interestingly, using MTT cell growth assay
(Figure 2B), we found that TZD, compared to DMSO, treatment could
promote PCa cell growth significantly in CWR22Rv1-siTR4 cells (left
panel). In contrast, TZD treatment showed little effect on PCa cell
growth compared toDMSOwhen theCWR22Rv1 cells were transfected
with scramble-siRNA control (CWR22Rv1-scr; right panel).
We then applied the second growth assay, anchorage-independent
growth assay, also known as colony formation assay, to confirm the
above TZD differential effects. As expected, TZD, compared to
DMSO, treatment could dramatically increase colony formation in
CWR22Rv1-siRNA (Figure 2C). In contrast, TZD, compared
to DMSO, treatment could decrease colony formation of
CWR22Rv1-scr (Figure 2D).
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Figure 5. TZD treatment has differential effect on HRAS expression. Quantitative PCR showed HRAS mRNA level in CWR22Rv1 (A) and
C4-2 (B) cells. Each cell line was divided into four sublines with various treatments for comparisons (scramble siRNA with DMSO,
scramble siRNA with TZD, TR4 siRNA with DMSO, and TR4 siRNA with TZD). In both cell lines, TZD decreases HRAS mRNA in the
scramble siRNA subline but increases HRAS mRNA in the TR4 siRNA subline. (C and D) HRAS promoter (2.2 kb) was cloned into the
luciferase reporter plasmid and then transfected into CWR22Rv1 or C4-2 with each cell line divided into the above four sublines. In both
cell lines, TZD decreases HRAS-luciferase activity in the scramble siRNA subline but increases HRAS-luciferase activity in the TR4 siRNA
subline (*P b 0.05, **P b 0.01, ***P b 0.001). FL/RL: firefly luciferase/renilla luciferase.
344 TZDs differential effects on prostate cancer Lin et al. Neoplasia Vol. 17, No. 4, 2015Together, results from Figure 2, A to D, using different growth
assays suggested that TZD treatment has differential effects on PCa
progression that depends on the TR4 expression status.
TZD Treatment–Altered PCa Cell Migration/Invasion Is
Linked to the TR4 Expression Status
To further study if TZD treatmentmight also have differential effects
on PCa metastasis, we applied the Boyden chamber migration/invasion
assays to examine the CWR22Rv1 metastatic ability. The results
revealed that TZD, compared to DMSO, treatment enhanced
CWR22Rv1-siTR4 cell migration significantly (Figure 3A). In contrast,
TZD, compared to DMSO, treatment decreased CWR22Rv1-scr cell
migration (Figure 3B).
For the invasion assay, we coated the membrane between the upper
and lower wells with Matrigel to mimic the in vivo invasion of the
cancer cells into the extracellular matrix. As shown in Figure 3C,
TZD, compared to DMSO, treatment increased CWR22Rv1-siTR4
invasion significantly. In contrast, TZD, compared to DMSO,
treatment slightly decreased CWR22Rv1-scr cell invasion
(Figure 3D). Importantly, to ensure that such important findings
are not just present in a single PCa cell line, we then repeated the
above studies described in Figures 2 to 3 with the PCa C4-2 cell line
and obtained similar results (Supplementary Figures 1 and 2).
Together, results from Figures 2, 3, Supplementary Figures 1
and 2 concluded that TZD treatment has differential effects on
PCa progression that depends on TR4 expression status, which
might suggest a potential risk to enhance the tumor progression
in those PCa patients with one allele TR4 deletion receiving
TZD treatment.TZD Treatment Enhanced PCa Progression In Vivo When
TR4 Is Knocked Down
To confirm that the above in vitro findings may also occur in the
in vivomouse model, we xenografted TZD-treated CWR22Rv1-scr and
CWR22Rv1-siTR4 cells into nude mouse anterior prostates and
sacrificed the mice at 4 weeks after inoculation. The results showed
that the CWR22Rv1-siTR4 mice grew larger tumors compared to the
CWR22Rv1-scr mice (Figure 4A). As expected, CWR22Rv1-siTR4
mice also had more metastatic PCa tumors than the CWR22Rv1-scr
mice (Figure 4B).
Together, the in vivo results from Figure 4, A and B, confirm the
in vitro findings that TZD could increase the PCa growth and
invasion depending on the TR4 expression level.
Mechanism Dissection and How TZD Treatment Has
Differential Effect on PCa Progression
To dissect the potential mechanism(s) by which the TZD
(rosiglitazone) has differential effects on PCa progression that may
depend on the expression status of TR4, we first screened 35
metastasis-related genes (Supplementary Table 1) and found that
HRAS oncogene mRNA increases in both PCa CWR22Rv1-siTR4
(Figure 5A) and C4-2-siTR4 (Figure 5B) treated with TZD but decreases
in the scramble controls treatedwithTZD.Furthermechanismdissection
using luciferase reporter assay also proved that TZDwas able to modulate
HRAS expression at the transcriptional levels when TR4 was knocked
down (Figure 5, C and D).
Importantly, we then applied the interruption approach by adding
50 μM RAS-specific inhibitor FTS for 2 weeks in CWR22Rv1 and
C4-2 stable sublines (scramble-siRNA-DMSO, scramble-siRNA-TZD,
CWR22Rv1 migration CWR22Rv1 invasion
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Figure 6. RAS-specific inhibitor FTS can interrupt the TZD-induced PCa migration and invasion. (A) Treatment with 50 μM RAS inhibitor
FTS successfully interrupted TZD-induced CWR22Rv1-siTR4 migration (bottom panel). FTS did not show any suppression effect in any of
the other three controls. (B) Treatment with 50 μM FTS successfully interrupted TZD-induced CWR22Rv1-siTR4 invasion (bottom panel).
FTS did not show any suppression effect in the other three controls. (C) Treatment with 50 μM FTS successfully interrupted TZD-induced
C4-2 siTR4migration (bottom panel). FTS did not show any suppression effect in any of the other three controls. (D) Treatment with 50 μM
FTS successfully interrupted TZD-induced C4-2-siTR4 invasion (bottom panel). FTS did not show any suppression effect in any of the other
three controls. The statistical results were calculated using Fisher exact test (*P b 0.05, **P b 0.01, ***P b 0.001).
Neoplasia Vol. 17, No. 4, 2015 TZDs differential effects on prostate cancer Lin et al. 345TR4-siRNA-DMSO, and TR4-siRNA-TZD and found that FTS
treatment could successfully interrupt TZD-induced PCa cell migration
and invasion in both CWR22Rv1 and C4-2 TR4 knocked down cell
lines (Figure 6, A–D), suggesting that TZD might need to functionthrough modulation of HRAS expression to have differential effects on
PCa progression that depends on the expression of TR4 (Figure 7).
Together, results from Figures 5 and 6 concluded that those PCa
patients with one allele TR4 deletion should be more cautious with
Figure 7. This schematic diagram depicts the TZD signaling through
TR4. The upper panel shows that in the TR4 wild-type condition TZD
cannot induce the HRAS expression and proliferation/invasion. The
bottom panel shows that in the TR4 knockdown condition TZD can
induce the HRAS expression and proliferation/invasion.
346 TZDs differential effects on prostate cancer Lin et al. Neoplasia Vol. 17, No. 4, 2015taking TZD or may consider additional treatment (for example, FTS
or other drugs) to eliminate the potential side effects.
Discussion
Among the clinical uses of many TZDs, troglitazone was the first
TZD to be approved in 1997 for the treatment of patients with type 2
diabetes. However, the severe hepatotoxicity side effect resulted in
drug withdrawal in 2000 [21]. Rosiglitazone was released in 1999 and
was found to have the potential of increased heart attack risk [22].
Pioglitazone was approved in 1999 and found to have the potential
side effect of increased bladder cancer risk and was withdrawn in
France [10].
Here, we found that treatment with the TZD rosiglitazone had
adverse effects when TR4 expression is knocked down. Given the fact
that TZD can transactivate both TR4 and PPARG, it is very likely
that TZD may have profound effects to activate PPARG in cells with
TR4 deletion. Under this circumstance, TZD may become an
enhancer to promote PCa progression. These results suggest that the
expression levels of TR4 and PPARG in PCa cells may need a balance
to maintain the proper and best TZD effects. Knocking down one of
them (TR4 in this study) may lead to unbalanced TZD effects that
may increase the risk for PCa progression (Figure 7).
Mechanism dissection revealed that the oncogene HRAS expression
was increasedwhenTR4was knocked down in cells and then treatedwith
TZD (Figure 5). HRAS plays important roles in regulating cellproliferation, differentiation, and survival [23]. Activated HRAS could
transduce the signal through the mitogen-activated protein kinase
(MAPK) pathway and promote tumorigenesis [24]. Accumulating
evidence supports that wild-type RAS can be chronically activated by
the aberrant autocrine/paracrine growth factor signals in various tumors
including PCa [25]. Importantly, the RAS/RAF/MAPK signals have also
been linked to the progression of PCa into the castration-resistant stage
[25]. Mice with transgenic RAS exhibited prostatic intraepithelial
neoplasia and metaplastic changes [26], suggesting the potential roles
for the promotion of PCa initiation. Furthermore, other reports also
showed that RAS might promote angiogenesis by inducing vascular
endothelial growth factor production that might be involved in the
metastasis [27]. Early studies also indicated that the activated RAS might
be able to promote metastasis in a non-metastatic rodent cell line [28,29],
as well as in the xenografted mouse model [30]. Mulholland et al. also
reported that RAS/MAPK activation together with PTEN loss could
promote metastasis from PCa stem/progenitor cells [31]. Together, the
results from in vitro cell lines, in vivo animals, and clinical studies all
suggest that RAS/MAPK activation plays critical roles in cancer
progression and metastasis.
Interestingly, in addition to the enhanced HRAS expression, we
also found the expression of RAF, a HRAS downstream target, was
enhanced when treating with TZD regardless of the TR4 level
(Supplementary Figure 3). Nevertheless, targeting HRAS signals with
the inhibitor FTS also successfully reversed the TZD-enhanced
tumor cell migration and invasion (Figure 6). These results suggest
that the combination of FTS with TZDmay potentially eliminate the
TZD side effects.
In summary, this study provides the first evidence showing that TZD
may have differential roles to affect PCa progression under different TR4
expression levels. People that have the genetic defect of TR4 deletion
caused by inheritance or mutation/deletion or any other molecules that
can alter TR4 expression in the PCa should be more careful because of
the potential side effects of being treated with TZD to battle diabetes.
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